checkAd
    Startseite > Aktien > Ligand Pharmaceuticals > Nachrichten
    Ligand Pharmaceuticals Aktie
    78,00
     
    EUR
    -3,70 %
    -3,00 EUR
    Letzter Kurs 13.05.24 Tradegate
    77,50
     
    EUR
    39 STK
    Geldkurs 08:35:30
    78,00
     
    EUR
    39 STK
    Briefkurs 08:35:30
    ISIN: US53220K5048 · WKN: A1C9RN · SYM: LGDN · USA

    Neueste Nachrichten

    Ligand Reports First Quarter 2024 Financial Results
    07.05.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
    07.05.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
    23.04.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
    08.04.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
    03.04.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
    05.03.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.03.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
    27.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa
    22.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
    16.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
    13.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    01.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals